Ongoing Clinical Trials for Guttate Psoriasis
There is currently 1 ongoing clinical trial for guttate psoriasis. This trial is investigating early treatment approaches using bimekizumab, a targeted injection therapy, compared with traditional topical steroid cream treatment. The study is being conducted in France and aims to understand whether early intervention with biological therapy can delay chronic inflammation in plaque psoriasis.
Clinical trial locations
Study on Early Treatment of Plaque Psoriasis with Bimekizumab and Clobetasol Propionate for Patients with Chronic Inflammation
This clinical trial is examining whether early treatment with a medication called bimekizumab can help delay the chronic inflammation associated with plaque psoriasis. The study compares bimekizumab, which is given as an injection under the skin, with a standard treatment using clobetasol propionate cream, a type of topical corticosteroid.
Who can participate:
- Adults between 18 and 45 years old
- People with plaque psoriasis but not psoriatic arthritis
- Those with mild psoriasis, measured by a PASI score between 2 and 6 (PASI is a standard way doctors measure how severe psoriasis is)
- Patients who have at least one psoriasis patch on their elbows, knees, or lower back
- People whose psoriasis has lasted either less than 6 months or more than 2 years
- Women of childbearing age must use effective birth control for at least one month before starting the study
- Participants must be enrolled in a social security system and able to attend all study visits
Who cannot participate:
- People who do not have psoriasis
- Those under 18 years old
- Members of vulnerable populations who cannot provide informed consent
What the study involves:
Participants will be assigned to one of two treatment groups. One group will apply clobetasol propionate cream to their skin as directed. The other group will receive bimekizumab injections at specified intervals. The treatment period lasts for 24 weeks, with assessments at weeks 16 and 24 to evaluate how well the treatment is working.
Throughout the study, which is expected to conclude by March 2028, participants will have regular check-ups to monitor their skin condition and overall health. The research team will assess the psoriasis using specific scales at weeks 16, 24, 48, 72, and 96. They will also analyze immune cells in the skin at the beginning and after 24 weeks of treatment.
Investigational drugs:
Bimekizumab is a type of medication called a monoclonal antibody. It works by targeting specific proteins in the body that are involved in the inflammation process. By blocking these proteins, bimekizumab may help reduce the symptoms of psoriasis and improve the appearance of the skin.
Topical corticosteroids are creams applied directly to the skin to help reduce inflammation. They work by suppressing the immune response in the skin, which can help decrease redness, swelling, and itching. In this study, the topical corticosteroid being used is clobetasol propionate cream.
Study goals:
The main goal of this trial is to assess whether early intervention with bimekizumab can improve outcomes for people with plaque psoriasis. By comparing it with traditional topical treatments, researchers hope to find better ways to manage this skin condition and improve the quality of life for those affected. The study will also evaluate how the immune system is affected by the treatments and monitor participants’ quality of life throughout the treatment period.
Summary
Currently, there is one active clinical trial for guttate psoriasis, being conducted in France. This study focuses on early intervention strategies, comparing the effectiveness of bimekizumab, a biological injection therapy that targets specific inflammatory proteins, with clobetasol propionate, a traditional topical corticosteroid cream.
The trial is specifically designed for younger adults with mild psoriasis and aims to understand whether early treatment with targeted biological therapy can delay chronic inflammation better than standard topical treatments. The study will run until 2028 and includes long-term follow-up assessments to evaluate the lasting effects of these treatment approaches.
This research represents an important investigation into whether newer biological therapies can provide better long-term outcomes when used early in the disease course, potentially changing how mild psoriasis is managed in younger patients.